Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD.

Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30788-0. doi: 10.1016/S1470-2045(19)30788-0. [Epub ahead of print]

PMID:
31859245
2.

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.

Elessa D, Talbot A, Lombion N, Harel S, Galicier L, Veyradier A, Joly B, Andreoli A, Rigaudeau S, Azoulay É, Coppo P, Royer B, Arnulf B.

Br J Haematol. 2020 Jan;188(2):338-340. doi: 10.1111/bjh.16333. Epub 2019 Dec 15. No abstract available.

PMID:
31840243
3.

Prognostic Value of Iodine-123-Metaiodobenzylguanidine Scintigraphy in Light-Chain Amyloidosis.

Nicol M, Baudet M, Cescau A, Harel S, Royer B, Sarda-Mantel L, Cohen-Solal A, Arnulf B, Logeart D.

Circ Cardiovasc Imaging. 2019 Nov;12(11):e009465. doi: 10.1161/CIRCIMAGING.119.009465. Epub 2019 Nov 4. No abstract available.

PMID:
31679392
4.

Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series.

Rech JS, Arnulf B, de Margerie-Mellon C, Talbot A, Malphettes M, Vignon M, Royer B, Lavergne D, Kambouchner M, Meignin V, Bergeron A, Prevot G, Brillet PY, Martinod E, Bridoux F, Nunes H, Jaccard A, Valeyre D, Uzunhan Y.

Am J Hematol. 2019 Nov;94(11):1214-1226. doi: 10.1002/ajh.25608. Epub 2019 Aug 23.

PMID:
31396978
5.

Diagnostic score of cardiac involvement in AL amyloidosis.

Nicol M, Baudet M, Brun S, Harel S, Royer B, Vignon M, Lairez O, Lavergne D, Jaccard A, Attias D, Macron L, Gayat E, Cohen-Solal A, Arnulf B, Logeart D.

Eur Heart J Cardiovasc Imaging. 2019 Jul 10. pii: jez180. doi: 10.1093/ehjci/jez180. [Epub ahead of print]

PMID:
31292624
6.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P.

Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: Lancet. 2019 Jun 14;:.

PMID:
31171419
7.

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P.

Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.

8.

Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin.

Dangien A, Beylot-Barry M, Battistella M, Ram-Wolff C, Talbot A, Rybojad M, Vergier B, Jachiet M, Bouaziz JD, Arnulf B, Bagot M, de Masson A.

Br J Dermatol. 2019 Sep;181(3):607-609. doi: 10.1111/bjd.17821. Epub 2019 May 13. No abstract available.

PMID:
30801660
9.

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study.

Joly F, Cohen C, Javaugue V, Bender S, Belmouaz M, Arnulf B, Knebelmann B, Nouvier M, Audard V, Provot F, Gnemmi V, Nochy D, Goujon JM, Jaccard A, Touchard G, Fermand JP, Sirac C, Bridoux F.

Blood. 2019 Feb 7;133(6):576-587. doi: 10.1182/blood-2018-09-872028. Epub 2018 Dec 21.

PMID:
30578255
10.

Coexisting cutaneous macroglobulinosis and scleredema of Buschke in a patient with a Waldenström Macroglobulinemia.

Roupie AL, Battistella M, Talbot A, Jachiet M, Bouaziz JD, Vignon-Pennamen MD, Royer B, Fermand JP, Arnulf B, Harel S.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e104-e106. doi: 10.1111/jdv.15268. Epub 2019 Feb 28. No abstract available.

PMID:
30267590
11.

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N.

Blood. 2018 Dec 6;132(23):2456-2464. doi: 10.1182/blood-2018-06-858613. Epub 2018 Sep 24.

12.

Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy.

Lozeron P, Mariani LL, Dodet P, Beaudonnet G, Théaudin M, Adam C, Arnulf B, Adams D.

Neurology. 2018 Jul 10;91(2):e143-e152. doi: 10.1212/WNL.0000000000005777. Epub 2018 Jun 15.

PMID:
29907605
13.

Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.

Hurabielle C, Battistella M, Ram-Wolff C, Fite C, Meignin V, Rivet J, Vignon-Pennamen MD, de Risi-Pugliese T, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Bagot M.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):405-412. doi: 10.1016/j.annder.2018.01.049. Epub 2018 Apr 14.

PMID:
29661476
14.

Cutis laxa associated with monoclonal gammopathy: 14 new cases and review of the literature.

Jachiet M, Harel S, Saussine A, Battistella M, Rybojad M, Asli B, Bengoufa D, Mahevas T, Bessis D, Galicier L, Schmutz JL, Hadj-Rabia S, Boutboul D, Lebbé C, Bagot M, Malphettes M, Lipsker D, Fermand JP, Bouaziz JD, Arnulf B; Study Group of Systemic Diseases in Dermatology (Étude des Maladies Systémiques en Dermatologie); Groupe d'Etude des Dermatoses Associées à une Immunoglobuline Monoclonale.

J Am Acad Dermatol. 2018 Nov;79(5):945-947. doi: 10.1016/j.jaad.2018.03.039. Epub 2018 Apr 3. Review. No abstract available.

PMID:
29621555
15.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
16.

KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia.

Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, Sicre de Fontbrune F, Peffault de Latour R, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M.

Br J Dermatol. 2018 Jul;179(1):197-199. doi: 10.1111/bjd.16322. Epub 2018 May 9. No abstract available.

PMID:
29315492
17.

Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy.

Provost CP, Tasseel-Ponche S, Lozeron P, Piccinini G, Quintaine V, Arnulf B, Kubis N, Yelnik AP.

J Rehabil Med. 2018 Feb 28;50(3):278-284. doi: 10.2340/16501977-2314.

18.

A case of multiple myeloma presenting with diffuse osteosclerosis and multiple bone infarcts.

Vignon M, Senot N, Bousson V, Meignin V, Frazier A, Arnulf B.

Joint Bone Spine. 2018 Oct;85(5):631-633. doi: 10.1016/j.jbspin.2017.11.013. Epub 2017 Dec 9. No abstract available.

PMID:
29233690
19.

Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.

Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, Lamy T, Wynckel A, Kolb B, Royer B, Rabot N, Benboubker L, Combe C, Jaccard A, Moulin B, Knebelmann B, Chevret S, Fermand JP; MYRE Study Group.

JAMA. 2017 Dec 5;318(21):2099-2110. doi: 10.1001/jama.2017.17924.

20.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

21.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X.

Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12.

PMID:
28697637
22.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S.

Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.

23.

Nucleotide excision repair is a potential therapeutic target in multiple myeloma.

Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas MA, Anderson KC, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC.

Leukemia. 2018 Jan;32(1):111-119. doi: 10.1038/leu.2017.182. Epub 2017 Jun 7.

24.

Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.

Baron M, Lozeron P, Harel S, Bengoufa D, Vignon M, Asli B, Malphettes M, Parquet N, Brignier A, Fermand JP, Kubis N, Arnulf B.

J Neurol. 2017 Jun;264(6):1132-1135. doi: 10.1007/s00415-017-8502-3. Epub 2017 May 8.

PMID:
28484839
25.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

26.

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.

Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T, Fouquet G, Guidez S, Harel S, Hebraud B, Javaugue V, Richez V, Schraen S, Touzeau C, Moreau P, Leleu X, Harding S, Chappell MJ.

Front Physiol. 2017 Mar 17;8:149. doi: 10.3389/fphys.2017.00149. eCollection 2017.

27.

Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy.

Vignon M, Placais L, Malphettes M, Bouaziz JD, Asli B, Bedossa P, Rivet J, Szalat R, Zagdanski AM, Rybojad M, Fermand JP, Baron M, Rautou PE, Arnulf B.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):e403-e405. doi: 10.1111/jdv.14213. Epub 2017 Mar 31. No abstract available.

PMID:
28295661
28.

Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy.

Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, Choukroun G, Delmas Y, Guerrot D, François A, Le Quintrec M, Javaugue V, Ribes D, Vrigneaud L, Arnulf B, Goujon JM, Ronco P, Touchard G, Bridoux F.

Blood. 2017 Mar 16;129(11):1437-1447. doi: 10.1182/blood-2016-08-737163. Epub 2017 Jan 9.

PMID:
28069603
29.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H.

Blood. 2016 Dec 22;128(25):2941-2948. doi: 10.1182/blood-2016-07-726778. Epub 2016 Oct 11.

30.

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, Royer B, Asli B, Knebelmann B, Touchard G, Jaccard A, Arnulf B, Bridoux F, Leung N, Fermand JP.

Leukemia. 2017 Jan;31(1):123-129. doi: 10.1038/leu.2016.195. Epub 2016 Jul 20.

PMID:
27435002
31.

Loss of tubular creatinine secretion as the only sign of tubular proximal cell dysfunction in light chain proximal tubulopathy: A case report.

Stehlé T, Vignon M, Flamant M, Figueres ML, Rabant M, Rodenas A, Noël LH, Arnulf B, Vidal-Petiot E.

Medicine (Baltimore). 2016 Jun;95(26):e3815. doi: 10.1097/MD.0000000000003815.

32.

Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?

Lozeron P, Ribrag V, Adams D, Brisset M, Vignon M, Baron M, Malphettes M, Theaudin M, Arnulf B, Kubis N.

J Neurol. 2016 Sep;263(9):1761-70. doi: 10.1007/s00415-016-8187-z. Epub 2016 Jun 17.

PMID:
27314957
33.

Catastrophic cryofibrinogenaemia associated with chronic lymphocytic leukaemia and salvage therapy using plasmapheresis and cyclophosphamide.

AlGain M, Damade R, Aucouturier F, Rivet J, Jachiet M, Malphettes M, Hickman G, Szalat R, Saussine A, de Masson A, Petit A, Rybojad M, Bagot M, Arnulf B, Bouaziz JD.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e38-e39. doi: 10.1111/jdv.13628. Epub 2016 Jun 14. No abstract available.

PMID:
27297832
34.

Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

Guinault D, Canet E, Huart A, Jaccard A, Ribes D, Lavayssiere L, Venot M, Cointault O, Roussel M, Nogier MB, Pichereau C, Lemiale V, Arnulf B, Attal M, Chauveau D, Azoulay E, Faguer S.

Br J Haematol. 2016 Sep;174(6):868-75. doi: 10.1111/bjh.14135. Epub 2016 Jun 12.

PMID:
27292694
35.

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

Bridoux F, Chen N, Moreau S, Arnulf B, Moumas E, Abraham J, Desport E, Jaccard A, Fermand JP.

Cancer Chemother Pharmacol. 2016 Jul;78(1):173-82. doi: 10.1007/s00280-016-3068-9. Epub 2016 Jun 10.

PMID:
27286995
36.

[Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment].

Cohen C, Javaugue V, Joly F, Arnulf B, Fermand JP, Jaccard A, Sirac C, Knebelmann B, Bridoux F, Touchard G.

Nephrol Ther. 2016 Jun;12(3):131-9. doi: 10.1016/j.nephro.2015.12.005. Epub 2016 Apr 21. Review. French.

PMID:
27117766
37.

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP.

J Clin Oncol. 2016 Jun 20;34(18):2125-32. doi: 10.1200/JCO.2015.63.1929. Epub 2016 Apr 25.

PMID:
27114594
38.

Idelalisib-related pneumonitis.

Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A.

Eur Respir J. 2016 Apr;47(4):1280-3. doi: 10.1183/13993003.01670-2015. Epub 2016 Feb 25. No abstract available.

39.

A rare case of disseminated skin and mucosal necrobiotic xanthogranuloma and xanthoma.

AlGain M, Szalat R, Vignon-Pennamen MD, Malphettes M, Vignon M, de Masson A, Bagot M, Rybojad M, Asli B, Arnulf B, Bouaziz JD.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e3-e5. doi: 10.1111/jdv.13577. Epub 2016 Jan 25. No abstract available.

PMID:
26810089
40.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

41.

The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile.

Szalat R, Monsel G, Le Goff W, Battistella M, Bengouffa D, Schlageter MH, Bouaziz JD, Arnulf B, Vignon M, Lesnik P, Saussine A, Malphettes M, Lazareth A, Vignon-Pennamen MD, Bagot M, Brouet JC, Fermand JP, Rybojad M, Asli B.

J Am Acad Dermatol. 2015 Nov;73(5):809-20. doi: 10.1016/j.jaad.2015.07.031. Epub 2015 Sep 11. Review.

PMID:
26365596
42.

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X.

Am J Hematol. 2015 Nov;90(11):1055-9. doi: 10.1002/ajh.24175. Epub 2015 Oct 6.

43.

[Pomalidomide for multiple myeloma].

Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X.

Rev Med Interne. 2015 Sep;36(9):613-8. doi: 10.1016/j.revmed.2015.04.007. Epub 2015 Aug 6. Review. French.

PMID:
26257103
44.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

45.

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, Knebelmann B, Jaccard A, Chevret S, Touchard G, Fermand JP, Arnulf B, Bridoux F.

Kidney Int. 2015 Nov;88(5):1135-43. doi: 10.1038/ki.2015.201. Epub 2015 Jul 15.

46.

Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients.

Chauvet S, Bridoux F, Ecotière L, Javaugue V, Sirac C, Arnulf B, Thierry A, Quellard N, Milin S, Bender S, Goujon JM, Jaccard A, Fermand JP, Touchard G.

Am J Kidney Dis. 2015 Nov;66(5):756-67. doi: 10.1053/j.ajkd.2015.03.035. Epub 2015 May 16.

PMID:
25987261
47.

Trogocytic intercellular membrane exchanges among hematological tumors.

LeMaoult J, Caumartin J, Daouya M, Switala M, Rebmann V, Arnulf B, Carosella ED.

J Hematol Oncol. 2015 Mar 14;8:24. doi: 10.1186/s13045-015-0114-8.

48.

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.

Delforge M, Minuk L, Eisenmann JC, Arnulf B, Canepa L, Fragasso A, Leyvraz S, Langer C, Ezaydi Y, Vogl DT, Giraldo-Castellano P, Yoon SS, Zarnitsky C, Escoffre-Barbe M, Lemieux B, Song K, Bahlis NJ, Guo S, Monzini MS, Ervin-Haynes A, Houck V, Facon T.

Haematologica. 2015 Jun;100(6):826-33. doi: 10.3324/haematol.2014.120121. Epub 2015 Mar 13.

49.

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Rekhtman G, Masliak Z, Robak P, Esseltine DL, Feng H, Deraedt W, van de Velde H, Arnulf B.

Haematologica. 2015 May;100(5):e207-10. doi: 10.3324/haematol.2014.118182. Epub 2015 Jan 16. No abstract available.

50.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

Leleu X, Karlin L, Macro M, Hulin C, Garderet L, Roussel M, Arnulf B, Pegourie B, Kolb B, Stoppa AM, Brechiniac S, Marit G, Thielemans B, Onraed B, Mathiot C, Banos A, Lacotte L, Tiab M, Dib M, Fuzibet JG, Petillon MO, Rodon P, Wetterwald M, Royer B, Legros L, Benboubker L, Decaux O, Escoffre-Barbe M, Caillot D, Fermand JP, Moreau P, Attal M, Avet-Loiseau H, Facon T; Intergroupe Francophone du Myélome (IFM).

Blood. 2015 Feb 26;125(9):1411-7. doi: 10.1182/blood-2014-11-612069. Epub 2015 Jan 9.

PMID:
25575538

Supplemental Content

Loading ...
Support Center